H1 2020 Osteoporosis Pipeline Review – Recognize Emerging Players – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Osteoporosis – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.

It provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 1, 8, 7, 22, 4, 63, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 13 and 13 molecules, respectively.

Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)

Reasons to Buy

  1. Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  2. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  3. Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
  4. Classify potential new clients or partners in the target demographic.
  5. Develop tactical initiatives by understanding the focus areas of leading companies.
  6. Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
  7. Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  8. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  9. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

  • Introduction
  • Osteoporosis – Overview
  • Osteoporosis – Therapeutics Development
  • Osteoporosis – Therapeutics Assessment
  • Osteoporosis – Companies Involved in Therapeutics Development
  • Osteoporosis – Drug Profiles
  • Osteoporosis – Dormant Projects
  • Osteoporosis – Discontinued Products
  • Osteoporosis – Product Development Milestones
  • Appendix

Companies Mentioned

  • Ablynx NV
  • Abreos Biosciences Inc
  • Addpharma Inc
  • Aerami Therapeutics
  • Affilogic SAS
  • AgeX Therapeutics Inc
  • AlphaMab Co Ltd
  • Altum Pharmaceuticals Inc
  • Amgen Inc
  • Aryogen Pharmed Co
  • Axsome Therapeutics Inc
  • Bainan Biotech ApS
  • BIOCND Inc
  • Biosion Inc
  • Bone Biologics Corp
  • Bristol-Myers Squibb Co
  • Cadila Healthcare Ltd
  • Cellatoz Therapeutics Inc
  • ChoDang Pharm Co Ltd
  • Chugai Pharmaceutical Co Ltd
  • Citragen Pharmaceuticals Inc
  • Corium, Inc.
  • CSPC Pharmaceutical Group Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Dong Wha Pharma Co Ltd
  • Dongkook Pharmaceutical Co Ltd
  • Eli Lilly and Co
  • EndoCeutics Inc
  • Enesi Pharma Ltd
  • Entera Bio Ltd
  • Enteris BioPharma Inc
  • Enzene Biosciences Ltd
  • Enzo Biochem Inc
  • Epygen Biotech Pvt Ltd
  • Evgen Pharma Plc
  • Galapagos NV
  • Genor BioPharma Co Ltd
  • GlycoNex Inc
  • GPN Therapeutics Inc
  • Haoma Medica Ltd
  • Helixmith Co Ltd
  • Hengenix Biotech Inc
  • Histide AG
  • HNB Therapeutics LLC
  • Hualan Biological Engineering Inc
  • Huons Co Ltd
  • Huons Global Co Ltd
  • IMGENEX India Pvt Ltd
  • Immunwork Inc
  • InnoPharmaScreen Inc
  • Innovent Biologics Inc
  • InSight Biopharmaceuticals Ltd
  • And Many More Companies!

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/h0sztp



Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900